49667-22-3

Basic information

• Product Name: 4-Methylsalicylamide
• Synonyms: 4-METHYL SALICYLAMIDE;2-HYDROXY-4-METHYLBENZAMIDE;Benzamide, 2-hydroxy-4-methyl- (9CI);4-METHYL SALICYLAMIDE HPLC 99+%;Benzamide,2-hydroxy-4-methyl-
• CAS NO: 49667-22-3
• Molecular Formula: C₈H₉NO₂
• Molecular Weight: 151.16
• Product Categories: AMIDE;Aromatic Carboxylic Acids, Amides, Anilides, Anhydrides & Salts
• Mol File: 49667-22-3.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 299.107 °C at 760 mmHg
• Flash Point: 134.695 °C
• Appearance: /
• Density: 1.23 g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.598
• CAS DataBase Reference: 4-Methylsalicylamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Methylsalicylamide(49667-22-3)
• EPA Substance Registry System: 4-Methylsalicylamide(49667-22-3)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 49667-22-3(Hazardous Substances Data)

Usage

Flammability and Explosibility

Nonflammable

InChI:InChI=1/C8H9NO2/c1-5-2-3-6(8(9)11)7(10)4-5/h2-4,10H,1H3,(H2,9,11)

Upstream product

• 24088-77-5 7-methyl-2H-[1,3]benzoxazine-2,4(3H)-dione 
• 4670-56-8 methyl 2-hydroxy-4-methylbenzoate 
• 6921-64-8 4'-hydroxy-2'-methylacetophenone 
• 14504-07-5 2-acetoxy-4-methylbenzoic acid 
• 57148-35-3 2-acetoxy-4-methyl-benzoyl chloride 
• 57839-59-5 6-Carbamoyl-3-methyl-2-cyclohexenone 
• 5977-14-0 acetoacetamido 

Downstream Products

• 877759-77-8 2-methoxy-4-methylbenzamide 
• 1056953-77-5 2-carbamoyl-5-methylphenyl acetate 
• 745047-94-3 N₁-(2-methoxy-4-methylbenzyl)-N₂-(2-(5-methylpyridin-2-yl)ethyl) oxalamide 
• 851670-22-9 (2-methoxy-4-methylphenyl)methanamine 
• 1263152-70-0 (R)-2-cyclohexyl-7-methyl-2H-benzo[e][1,3]oxazin-4(3H)-one 
• 1263152-73-3 (R)-7-methyl-2-phenyl-2H-benzo[e][1,3]oxazin-4(3H)-one 
• 1263152-71-1 (R)-2-benzyl-7-methyl-2H-benzo[e][1,3]oxazin-4(3H)-one 
• 50-85-1 2-hydroxy-p-toluic acid 
• 861318-40-3 bis-(2-hydroxy-4-methyl-benzoyl)-amine 

Relevant articles and documents

Asymmetric Hydrogenation of Cationic Intermediates for the Synthesis of Chiral N,O-Acetals

For over half a century, transition-metal-catalyzed homogeneous hydrogenation has been mainly focused on neutral and readily prepared unsaturated substrates. Although the addition of molecular hydrogen to C=C, C=N, and C=O bonds represents a well-studied paradigm, the asymmetric hydrogenation of cationic species remains an underdeveloped area. In this study, we were seeking a breakthrough in asymmetric hydrogenation, with cationic intermediates as targets, and thereby anticipating applying this powerful tool to the construction of challenging chiral molecules. Under acidic conditions, both N- or O-acetylsalicylamides underwent cyclization to generate cationic intermediates, which were subsequently reduced by an iridium or rhodium hydride complex. The resulting N,O-acetals were synthesized with remarkably high enantioselectivity. This catalytic strategy exhibited high efficiency (turnover number of up to 4400) and high chemoselectivity. Mechanistic studies supported the hypothesis that a cationic intermediate was formed in situ and hydrogenated afterwards. A catalytic cycle has been proposed with hydride transfer from the iridium complex to the cationic sp2 carbon atom being the rate-determining step. A steric map of the catalyst has been created to illustrate the chiral environment, and a quantitative structure–selectivity relationship analysis showed how enantiomeric induction was achieved in this chemical transformation.

Method of treating a patient having precancerous lesions with phenyl purinone derivatives

Derivatives of Phenyl Purinone are useful for the treatment of patients having precancerous lesions. These compounds are also useful to inhibit growth of neoplastic cells.

2-Substituted purinone having phosphodiesterase inhibitory activity

This invention relates to phenylpurinone derivatives which have bronchodilator and anti-allergic activities. A compound of the invention is 2-(2-propoxy-5-chlorophenyl)purin-6-one.